- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02942368
Adaptive tDCS for Treatment-Resistant MDD
December 4, 2023 updated by: Washington University School of Medicine
Adaptive Transcranial Direct Current Stimulation as an Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder
This pilot study aims to investigate the potential role of transcranial direct current stimulation (tDCS) in the treatment of treatment-resistant major depressive disorder (MDD).
tDCS is a noninvasive brain stimulation technique which has been utilized for the treatment of major depression in several studies, both as a primary and adjunctive treatment.
The treatment will be administered under the supervision of a physician with experience in administering the treatment and monitoring for complications.
This will be a prospective "adaptive tDCS stimulation" open label research study.
Participants will receive 20 minute sessions of up to 4 milliamps (mA) transcutaneous electrical stimulation sessions over 4 to 6 weeks.
Building on the theory that greater current "dose" may be a significant factor in determining efficacy, this study aims to determine whether higher tDCS current doses lead to greater improvements in depressive symptoms in this population of patients with treatment-resistant major depressive disorder.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in Saint Louis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults age 18 to 65
- History of major depressive disorder with current depressive symptoms, as defined by DSM-IV criteria
- Baseline score of Hamilton Depression Rating Scale 17-item (HDRS-17) score of 17 or higher
- Failure of at least 3 prior lifetime antidepressant trials
- Good command of the English language
Exclusion Criteria:
Lifetime history of the following, defined by DSM-IV criteria per study physician:
- Moderate or severe substance use disorder in the past 6 months with the exception of nicotine use disorder
- Dementia or major neurocognitive disorder
- Schizophrenia spectrum disorders
- Autism spectrum disorder
- Depression which has failed to respond to ECT, with treatment failure as determined by evaluating physician
- Failure of greater than 6 antidepressant trials in the current depressive episode
Current evidence of the following, defined by present symptomology as per study physician:
- Active psychotic symptoms
- Bipolar disorder with a current manic, hypomanic, or mixed episode as defined by DSM-IV criteria
- Depression secondary to a general medical illness
- Dysphoria better explained by a personality disorder
- Dysphoria associated with a primary anxiety disorder or PTSD
- Active suicidal intention (inability to contract for safety)
- Any change in psychotropic medication within 30 days of the initiation of tDCS
- History of neurological disorders (e.g., epilepsy) and/or off any treatment medication for a neurological disorder for minimum 3 years (36 months)
- Any open wounds (e.g., blisters, burns including sun burns, cuts or irritation) under or near the scalp regions where electrodes are placed
- Metal implants (e.g., Deep Brain Stimulator, Vagus Nerve Stimulator)
- Any skin disorders (e.g., eczema, severe rashes, sensitive skin, any communicable skin disorder or treatment for a communicable skin disorder in the past 12 months) or other skin defects which compromise the integrity of the skin at or near stimulation locations (where electrodes are placed)
- Any history of head injury resulting in unconsciousness for more than 5 minutes (e.g., head trauma, brain surgery)
- Metallic face or scalp tattoos
- Any chronic headaches or migraines (occurring for consecutive days and are longer than an hour)
- If a participant has a change in the rate or severity of head pressure, headache, or migraine in the past two weeks, they will also be excluded as per study clinician as we are not aiming to assess the treatment of headache with tDCS
- Any personal history of seizures.
- Currently pregnant or lactating, as determined in part from urine pregnancy test at Screening/Baseline appointment and medical history.
- Any other factor that in the investigators' judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tDCS
Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks.
Treatments will take place daily, 5 days per week.
|
Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement in depressive symptoms as measured by mean change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to end of the study.
Time Frame: Measurements at week 0, week 2, week 4, week 5 and week 6
|
Measurements at week 0, week 2, week 4, week 5 and week 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Charles Conway, MD, Washington University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 14, 2017
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
October 21, 2016
First Submitted That Met QC Criteria
October 21, 2016
First Posted (Estimated)
October 24, 2016
Study Record Updates
Last Update Posted (Actual)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 4, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6610-201610133
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Treatment-Resistant
-
Wayne Goodman MDActive, not recruitingTreatment Resistant Major Depressive DisorderUnited States
-
Taipei Veterans General Hospital, TaiwanRecruitingMajor Depressive Disorder | Treatment-resistant DepressionTaiwan
-
Taipei Veterans General Hospital, TaiwanRecruitingMajor Depressive Disorder | Treatment-resistant DepressionTaiwan
-
National Institute of Mental Health (NIMH)Taisho Pharmaceutical Co., Ltd.RecruitingDepression | Major Depressive Disorder | Treatment-Resistant DepressionUnited States
-
Medical University of GdanskPerception NeuroscienceEnrolling by invitationMajor Depressive Disorder | Treatment-Resistant DepressionPoland
-
Mclean HospitalMassachusetts General Hospital; PfizerTerminatedTreatment-Resistant DepressionUnited States
-
University of GreifswaldGerman Research Foundation; Charite University, Berlin, Germany; Hannover Medical... and other collaboratorsRecruitingTreatment-resistant Depression | Persistent Depressive DisorderGermany
-
University Health Network, TorontoCentre for Addiction and Mental HealthRecruitingDepression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant DepressionCanada
-
Paul J. LamotheUnknownTreatment-Resistant Depression | Depressive Disorder,Mexico
-
Entheon Biomedical Corp.CompletedTreatment-resistant DepressionUnited States
Clinical Trials on tDCS
-
Hôpital le VinatierCompletedSchizophrenia | Auditory HallucinationsFrance, Tunisia
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Enrolling by invitationSubstance-Related DisordersSpain
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)Unknown
-
Nachum Soroker, MDUnknown
-
Bambino Gesù Hospital and Research InstituteCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedMotor Activity | Motor NeuroplasticityUnited States
-
Charite University, Berlin, GermanyCompletedMigraine With Aura | CADASIL | Cerebral Microangiopathy | ICA StenosisGermany
-
Universidade Federal de PernambucoCompleted
-
Thorsten RudroffTerminatedMultiple Sclerosis | Neuropathic PainUnited States
-
University of MichiganNational Institute of Mental Health (NIMH)Completed